Navigation Links
Early Adopter of INFORM HER2 Dual ISH Assay Optimistic About Impact on Patient Care, Hospital Bottom Line
Date:9/12/2011

assays to test for HER2 gene amplification. These assays must be run manually by skilled technologists, making them extremely labor-intensive and time consuming.

HER2 Dual ISH Technology; 'Adds Significant Medical Value for The Patient'

Breast cancer is the second leading cause of cancer-related death among women. An estimated 207,090 new cases of breast cancer were diagnosed in the United States during 2010 and close to 39,800 women died from the disease, according to the National Cancer Institute. About 20 percent of women diagnosed with breast cancer are HER2-positive.

The HER2 Dual ISH assay measures the number of copies of the HER2 gene in tumor tissue. Defining a patient's HER2 status allows the treatment team to predict response to Herceptin therapy, which has been clinically proven to improve outcomes for patients with HER2-positive breast cancer.

With the HER2 Dual ISH assay, the HER2 gene status is determined on a single slide using a standard light microscope. Unlike FISH assays, the HER2 Dual ISH assay uses robust brightfield detection technology to deliver results that are easily interpreted, and the signals do not fade over time.  This allows the actual slides to be stored long term and easily shared between pathologists and oncologists.

"This new technology will impact our practice in many positive ways -- one of the most important is the ability to archive the slides," says Dr. Lauren LeBeau, UMC breast cancer specialist and assistant professor of pathology. "Using the HER2 Dual ISH assay, we can easily show the slides and share with the treatment team how and why we interpreted slides the way we did. We work with the oncologists to make critical diagnostic decisions, and being able to view all the information possible will lead to a greater continuity of patient care."

The FDA approval of HER2 Dual ISH in June of 2011 was based on a U.S. study involving tumor samples from 510 patients with breas
'/>"/>

SOURCE Ventana Medical Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. SBRT for Medically Inoperable Early Stage Lung Cancer a Key Topic for Elekta Presenters at Lung Cancer Conference
2. Morphotek, Inc. Employees Collect Nearly 9,000 Pounds of Food for Local Families
3. FDA Sets Meeting Date in Early June to Discuss Re-submission of Pixantrone NDA for Accelerated Approval
4. Life Technologies and ProBioGen AG Announce Freedom™ Cell Line Development Royalty-Free Kits To Advance Early Stage Biologic Drug Production
5. Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
6. Early Diagnosis and Treatment the Focus of International Dialogue on Primary Immunodeficiency Disease
7. Phreesia Screening Tool Helps Physician Practices with Autism Early Detection
8. After the ABRF Conference: Gene Codes Flooded with Requests for Early Access to NextGen Software Tools
9. New Pneumococcal Vaccine Approach Successful in Early Tests
10. How now, inside the cow: Nearly 30,000 novel enzymes for biofuel production improvements
11. Reimbursement Rate Nearly Tripled for Cylexs ImmuKnow® Assay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... The DNA Microarray market market was valued at ... grow at a CAGR of 15.2% from 2014 ... the DNA Microarray for an in-depth analysis of ... various tables and figures. , http://www.micromarketmonitor.com/market-report/dna-microarray-reports-5177428198.html ... instrument, consumables, and services, where the consumables market ...
(Date:12/13/2014)... New York (PRWEB) December 13, 2014 ... its global network and Cold Chain capabilities, and is ... Tower in Paris, France, to serve Life Science clients ... facility equipped with a controlled-ambient warehouse, will provide 24/7 ... for vaccines and investigational drugs, patient-clinical specimens, API, following ...
(Date:12/13/2014)... N.J. and SAN ANTONIO ... LLC (Janssen) today announced the presentation of data at ... Phase 3 EPO-ANE-3010 study evaluating epoetin alfa plus best ... anemia in patients with metastatic breast cancer receiving standard ... objective, which was to rule out a 15 percent ...
(Date:12/12/2014)... December 11, 2014 Electronic Data ... for claims management and supply chain management to ... of transactions. The benefits associated with the use ... time of transactions has helped improve the acceptance ... Browse 70 market data tables and 107 figures ...
Breaking Biology Technology:DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 2DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 4Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 2The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 3The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 4
... that a new market research report is available in its ... and companies http://www.reportlinker.com/p0203543/Gene-Therapy---technologies-markets-and-companies.html ... on gene therapy with 72 tables and 13 figures ... 700 selected references from the literature - Estimates ...
... Dec. 21, 2010 Exagen Diagnostics, Inc., a specialty ... today announced that it has been awarded $400,000 in ... program, which was created by Congress as part of ...  Proceeds from the grants will be used to advance ...
... Mass. and BRANFORD, Conn., Dec. 20, 2010 ... oncology-focused molecular diagnostics company, and HistoRx, Inc., ... to advance individualized patient care, today announced ... Metamark a worldwide license to the AQUA ...
Cached Biology Technology:Reportlinker Adds Gene Therapy - technologies, markets and companies 2Reportlinker Adds Gene Therapy - technologies, markets and companies 3Reportlinker Adds Gene Therapy - technologies, markets and companies 4Reportlinker Adds Gene Therapy - technologies, markets and companies 5Reportlinker Adds Gene Therapy - technologies, markets and companies 6Reportlinker Adds Gene Therapy - technologies, markets and companies 7Reportlinker Adds Gene Therapy - technologies, markets and companies 8Reportlinker Adds Gene Therapy - technologies, markets and companies 9Reportlinker Adds Gene Therapy - technologies, markets and companies 10Reportlinker Adds Gene Therapy - technologies, markets and companies 11Reportlinker Adds Gene Therapy - technologies, markets and companies 12Reportlinker Adds Gene Therapy - technologies, markets and companies 13Reportlinker Adds Gene Therapy - technologies, markets and companies 14Reportlinker Adds Gene Therapy - technologies, markets and companies 15Reportlinker Adds Gene Therapy - technologies, markets and companies 16Reportlinker Adds Gene Therapy - technologies, markets and companies 17Reportlinker Adds Gene Therapy - technologies, markets and companies 18Reportlinker Adds Gene Therapy - technologies, markets and companies 19Reportlinker Adds Gene Therapy - technologies, markets and companies 20Reportlinker Adds Gene Therapy - technologies, markets and companies 21Exagen Diagnostics Awarded $400,000 in Grants Under the QTDP Program 2Metamark and HistoRx Announce Licensing Agreement for AQUA® Technology 2
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
(Date:12/3/2014)... Dec. 2, 2014   Marvin Test Solutions ... test solutions for military, aerospace, and manufacturing organizations, ... its successful TS-900 PXI semiconductor test platform ... of high-end systems to customers at a fraction ... to traditional ATE. "Our semiconductor ...
(Date:11/21/2014)... Wash. , Nov. 20, 2014 C-Labs ... for the Internet of Things (IoT), today announced the ... of chief operating officer. Previously a strategic advisor to ... finance, and operations. Mr. Traynor is based out of ... . He reports to Chris Muench , Chief ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... see the flowers of Edinburgh in full bloom in the depths ... the impact of global warming on spring flowering, published today in ... dating back to the late nineteenth century, has been used to ... further warming will have on plant life by the year 2080. ...
... faster than in any other location on Earth. Researchers at ... indicating that the changes are astonishingly fast. Many original species ... species from southern areas to migrate north, where they occupy ... renowned Science magazine will publish a joint article ...
... ANN ARBOR, Mich.---The growth of cancerous tumors is ... free radicals---highly reactive oxygen-containing molecules. It stands to ... antioxidants, which inhibit the rogue radicals, or with pro-oxidants, ... cancer cells to the point of vanquishing them. ...
Cached Biology News:Early spring time for Edinburgh? Study predicts effect of global warming on spring flowers 2The change in Arctic nature foreshadows the global environment of the future 2New method monitors early sign of oxidative stress in cancer 2
... to Dideoxycytidine Dideoxycytidine is a cytidine analog ... inhibiting retroviral activity. Immunogen: Chemical ... Specificity: The specificity of the ddC antiserum ... moles of ddC to moles of ddC analog ...
... The Jouan MSC series of ... comfortable working conditions and certification to ... automatic regulation ensures that the cabinets ... working conditions. Natural lighting, low noise ...
... features, the 1400 Series will maximize your comfort level ... every time you use it. , Energy ... by as much as 50% from competitive models, saving ... cabinet. Multiply this savings by the number of ...
... with circular clear acrylic chamber for complete ... Oven features microprocessor operation for precise mixing ... unit., Carousel rotates at 11 rpm; ... removable , Bottle Capacity - four ...
Biology Products: